New hope for lung cancer patients: drug combo targets tough tumors
Disease control
Not yet recruiting
This phase 3 study tests whether a new combination of drugs (HS-20093 plus adebrelimab) works better than the standard chemotherapy docetaxel for people with advanced or metastatic non-squamous non-small cell lung cancer that has already been treated. The study will enroll about …
Phase: PHASE3 • Sponsor: Hansoh BioMedical R&D Company • Aim: Disease control
Last updated May 01, 2026 15:59 UTC